1,183
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Risk factors for readmission for hyperbilirubinemia in neonates with ABO hemolytic disease: a single-center retrospective cohort study

ORCID Icon, , , &
Article: 2238106 | Received 20 Jul 2022, Accepted 13 Jul 2023, Published online: 24 Jul 2023

References

  • Zhou S, Wu X, Ma A, et al. Analysis of therapeutic effect of intermittent and continuous phototherapy on neonatal hemolytic jaundice. Exp Ther Med. 2019;17:4007–4012.
  • Bhutani VK, Wong R. Bilirubin-induced neurologic dysfunction (BIND). Semi Fetal Neonatal Med. 2015;20(1):1. doi:10.1016/j.siny.2014.12.010.
  • Ma XL, Chen Z, Zhu JJ, et al. Management strategies of neonatal jaundice during the coronavirus disease 2019 outbreak. World J Pediatr. 2020;16(3):247–250. doi:10.1007/s12519-020-00347-3.
  • Pan J, Zhan C, Yuan T, et al. Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study. J Perinatol. 2021;41(6):1397–1402. doi:10.1038/s41372-021-00963-5.
  • Anne RP, Rahiman EA. Prediction of neonatal hyperbilirubinemia using 1st day serum bilirubin levels: correspondence. Indian J Pediatr. 2019;86(12):1166. doi:10.1007/s12098-019-03018-y.
  • Tavakolizadeh R. Risk factors associated with neonatal jaundice: a cross-sectional study from Iran. Open Access Maced J Med Sci. 2018;6(8):1387–1393.
  • Thielemans L, Trip-Hoving M, Landier J, et al. Indirect neonatal hyperbilirubinemia in hospitalized neonates on the Thai–Myanmar border: a review of neonatal medical records from 2009 to 2014. BMC Pediatr. 2018;18(1):190. doi:10.1186/s12887-018-1165-0.
  • Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339. doi:10.1371/journal.pmed.1001339.
  • Daunhawer I, Kasser S, Koch G, et al. Enhanced early prediction of clinically relevant neonatal hyperbilirubinemia with machine learning. Pediatr Res. 2019;86(1):122–127. doi:10.1038/s41390-019-0384-x.
  • Khurana R, Batra P, Faridi MMA, et al. Revisiting ABO incompatibility as a risk factor for significant neonatal hyperbilirubinemia. Trop Doct. 2019;49(3):201–204. doi:10.1177/0049475519838428.
  • Bhutani BK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999;103(1):6–14. doi:10.1542/peds.103.1.6.
  • American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.
  • Bhutani VK, the Committee on Fetus and Newborn, American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2011;128(4):e1046–e1052. doi:10.1542/peds.2011-1494.
  • Chang PW, Newman TB. A simpler prediction rule for rebound hyperbilirubinemia. Pediatrics. 2019;144(1):e20183712. doi:10.1542/peds.2018-3712.
  • Elhawary IM, Abdel Ghany EAG, Aboelhamed WA, et al. Incidence and risk factors of post-phototherapy neonatal rebound hyperbilirubinemia. World J Pediatr. 2018;14(4):350–356. doi:10.1007/s12519-018-0119-9.
  • Barak M, Berger I, Dollberg S, et al. When should phototherapy be stopped? A pilot study comparing two targets of serum bilirubin concentration. Acta Paediatr. 2008;98(2):277–281. doi:10.1111/j.1651-2227.2008.01015.x.
  • Chang PW, Kuzniewicz MW, McCulloch CE, et al. A clinical prediction rule for rebound hyperbilirubinemia following inpatient phototherapy. Pediatrics. 2017;139(3):e20162896. doi:10.1542/peds.2016-2896.
  • Sachdeva M, Murki S, Oleti TP, et al. Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 34 weeks of gestational age: a randomized controlled trial. Eur J Pediatr. 2015;174(2):177–181. doi:10.1007/s00431-014-2373-8.
  • Tsujimae SY, Yamana K, et al. Hyperbilirubinemia in term newborns needing phototherapy within 48 hours after birth in a Japanese Birth Center. Kobe J Med Sci. 2018;64(1):E20–E25.
  • Zantek ND, Koepsell SA, Tharp DR Jr., et al. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87(7):707–709. doi:10.1002/ajh.23218.
  • Van Rossum HH, de Kraa N, Thomas M, et al. Comparison of the direct antiglobulin test and the eluate technique for diagnosing haemolytic disease of the newborn. Pract Lab Med. 2015;3:17–22. doi:10.1016/j.plabm.2015.10.001.
  • Desjardins L, Blajchman MA, Chintu C, et al. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr. 1979;95(3):447–449. doi:10.1016/S0022-3476(79)80533-8.
  • Xu C, Bao Y, Zhu J. Remote monitoring of neonatal jaundice in newborns with ABO hemolytic disease. J Zhejiang Univ. 2020;10(12):651–655.